IPP Bureau
EMA approves Pfizer’s Covid-19 anti-viral candidate
By IPP Bureau - December 17, 2021
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Boyd Corporation acquires MBK Tape Solutions
By IPP Bureau - December 17, 2021
Medical footprint expansion with deeper medical grade skin contact material science expertise
Alloy Therapeutics acquires deepCDR Biologics to bring ML into drug discovery
By IPP Bureau - December 17, 2021
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination
By IPP Bureau - December 17, 2021
Effectiveness of Covaxin against the Omicron variant is currently being studied
Noorik Biopharma signs contract with Switzerland to develop ambrisentan to treat severe Covid-19
By IPP Bureau - December 16, 2021
The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others
Cipla acquires stake in Clean Max Auriga Power
By IPP Bureau - December 16, 2021
Clean Max Auriga Power is a special purpose vehicle engaged in the business of production, supply and distribution of solar and wind or other renewable energy generation plant
Sun gets US FDA approval for generic amphotericin B injection
By IPP Bureau - December 16, 2021
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
U.S. FDA approves Bristol Myers Squibb’s Orencia
By IPP Bureau - December 16, 2021
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Vakrangee partners with PharmEasy to deliver medicines to remote areas
By IPP Bureau - December 16, 2021
Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country
Serial entrepreneur Sanjeev Dahiwadkar joins RaphaCure Board
By IPP Bureau - December 16, 2021
Dahiwadkar currently heads four technology companies- WipeOut Inc, Cognota Healthcare Technologies, IT Shastra India and Moringa Techsolv, which he has founded
Glamyo Health collaborates with DocKnee for orthopaedic surgeries
By IPP Bureau - December 16, 2021
After specialising in laparoscopy, proctology, urology, and cosmetic surgeries, Glamyo Health is now venturing into orthopaedic surgeries
Syngene extends contract with Amgen till 2026
By IPP Bureau - December 16, 2021
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
USFDA grants Orphan Drug Designation to Zydus’ novel compound to treat malaria
By IPP Bureau - December 16, 2021
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
NATCO Pharma to acquire Dash Pharmaceuticals
By IPP Bureau - December 15, 2021
The cash consideration for the acquisition is US$ 18 million.
NephroPlus raises US $ 24 mn in E round to fund expansion
By IPP Bureau - December 15, 2021
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
